Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
RECTICEL [BE0003656676/REC]   
[27/04/2021]

RECTICEL : Recticel trading update 1st quarter 2021

See more
 
ECONOCOM GROUP [BE0974313455/ECONB]   
[26/04/2021]

ECONOCOM GROUP : Opérations réalisées sur l’action Econocom

pCommuniqué de presse 26 avril 2021/p pAu cours de la période du 19/04/2021 au 25/04/2021, une filiale indirecte de la société Econocom Group SE à savoir BIS Bedrijfs Informatie Systemen B.V. a acquis un total de 857 981 actions Econocom Group pour un prix total de 2 958 359,77 euros./p pAu 26 avril 2021, BIS Bedrijfs Informatie Systemen B.V. détient... See more
 
UCB [BE0003739530/UCB]   
[23/04/2021]

UCB : UCB Media Room: Acquisitions and disposals of own shares

https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg Acquisitions of own shares and disposals of own shares Brussels Belgium, 23 April 2021 =E2=80=93 20:00 CEST =E2=80=93 regulate= d information Acquisitions of own shares In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi= ng the Belgian Code on Companies and Associations, UCB SA/NV... See more
 
UCB [BE0003739530/UCB]   
[23/04/2021]

UCB : UCB Media Room: UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021 Brussels, Belgium =E2=80=93 April 23, 2021, 16:15 CEST =E2=80=93 UCB, a glo= bal biopharmaceutical company, today announced that 12 abstracts on bimekiz= umab, an investigational IL17A and IL17F inhibitor, in the treatment of a= dults with moderate to severe... See more
 
UCB [BE0003739530/UCB]   
[23/04/2021]

UCB : UCB Media Room: bimekizumab in the New England Journal of Medicine

https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg The New England Journal of Medicine Publishes Results from Two Bimekizum= ab Phase 3 Studies in Moderate to Severe Plaque Psoriasis =C2=B7 Today, two manuscripts published back to back detail the full result= s from the BE RADIANT and BE SURE studies, comparing the efficacy and safet= y of bimekizumab to secukinumab and...